vs
AtriCure, Inc.（ATRC）与Shoals Technologies Group, Inc.（SHLS）财务数据对比。点击上方公司名可切换其他公司
AtriCure, Inc.的季度营收约是Shoals Technologies Group, Inc.的1.0倍（$141.2M vs $140.6M），AtriCure, Inc.净利率更高（0.1% vs -0.2%，领先0.3%），Shoals Technologies Group, Inc.同比增速更快（74.9% vs 14.3%），过去两年Shoals Technologies Group, Inc.的营收复合增速更高（19.0% vs 10.2%）
AtriCure是一家专注于心房颤动及相关心脏病症治疗的医疗设备企业，研发并生产创新外科手术工具与疗法，主要服务北美、欧洲、亚太地区的医院、心脏外科中心及医疗机构，为微创心脏手术提供高效可靠的适配解决方案。
Shoals科技集团是可再生能源及电动出行领域的电气系统平衡解决方案供应商，核心产品覆盖光伏、储能及充电桩用连接组件，主要服务北美、欧洲、亚太市场的公用事业、工商业及民用客户。
ATRC vs SHLS — 直观对比
营收规模更大
ATRC
是对方的1.0倍
$140.6M
营收增速更快
SHLS
高出60.6%
14.3%
净利率更高
ATRC
高出0.3%
-0.2%
两年增速更快
SHLS
近两年复合增速
10.2%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $141.2M | $140.6M |
| 净利润 | $108.0K | $-297.0K |
| 毛利率 | 77.4% | 29.2% |
| 营业利润率 | 23.0% | 5.5% |
| 净利率 | 0.1% | -0.2% |
| 营收同比 | 14.3% | 74.9% |
| 净利润同比 | — | -5.3% |
| 每股收益（稀释后） | $0.00 | $0.00 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ATRCSHLS
| Q1 26 | $141.2M | $140.6M | ||
| Q4 25 | $140.5M | $148.3M | ||
| Q3 25 | $134.3M | $135.8M | ||
| Q2 25 | $136.1M | $110.8M | ||
| Q1 25 | $123.6M | $80.4M | ||
| Q4 24 | $124.3M | $107.0M | ||
| Q3 24 | $115.9M | $102.2M | ||
| Q2 24 | $116.3M | $99.2M |
净利润ATRCSHLS
| Q1 26 | $108.0K | $-297.0K | ||
| Q4 25 | — | $8.1M | ||
| Q3 25 | $-267.0K | $11.9M | ||
| Q2 25 | $-6.2M | $13.9M | ||
| Q1 25 | $-6.7M | $-282.0K | ||
| Q4 24 | — | $7.8M | ||
| Q3 24 | $-7.9M | $-267.0K | ||
| Q2 24 | $-8.0M | $11.8M |
毛利率ATRCSHLS
| Q1 26 | 77.4% | 29.2% | ||
| Q4 25 | 75.0% | 31.6% | ||
| Q3 25 | 75.5% | 37.0% | ||
| Q2 25 | 74.5% | 37.2% | ||
| Q1 25 | 74.9% | 35.0% | ||
| Q4 24 | 74.5% | 37.6% | ||
| Q3 24 | 74.9% | 24.8% | ||
| Q2 24 | 74.7% | 40.3% |
营业利润率ATRCSHLS
| Q1 26 | 23.0% | 5.5% | ||
| Q4 25 | 1.8% | 11.7% | ||
| Q3 25 | 0.2% | 13.7% | ||
| Q2 25 | -4.5% | 14.4% | ||
| Q1 25 | -4.8% | 5.4% | ||
| Q4 24 | -11.7% | 15.4% | ||
| Q3 24 | -6.4% | 4.4% | ||
| Q2 24 | -6.2% | 18.7% |
净利率ATRCSHLS
| Q1 26 | 0.1% | -0.2% | ||
| Q4 25 | — | 5.5% | ||
| Q3 25 | -0.2% | 8.7% | ||
| Q2 25 | -4.5% | 12.5% | ||
| Q1 25 | -5.5% | -0.4% | ||
| Q4 24 | — | 7.3% | ||
| Q3 24 | -6.8% | -0.3% | ||
| Q2 24 | -6.9% | 11.9% |
每股收益（稀释后）ATRCSHLS
| Q1 26 | $0.00 | $0.00 | ||
| Q4 25 | $0.04 | $0.05 | ||
| Q3 25 | $-0.01 | $0.07 | ||
| Q2 25 | $-0.13 | $0.08 | ||
| Q1 25 | $-0.14 | $0.00 | ||
| Q4 24 | $-0.33 | $0.04 | ||
| Q3 24 | $-0.17 | $0.00 | ||
| Q2 24 | $-0.17 | $0.07 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $146.2M | $1.9M |
| 总债务越低越好 | $61.0M | — |
| 股东权益账面价值 | $491.7M | $601.6M |
| 总资产 | $644.0M | $1.0B |
| 负债/权益比越低杠杆越低 | 0.12× | — |
8季度趋势，按日历期对齐
现金及短期投资ATRCSHLS
| Q1 26 | $146.2M | $1.9M | ||
| Q4 25 | $167.4M | $7.3M | ||
| Q3 25 | $147.9M | $8.6M | ||
| Q2 25 | $117.8M | $4.7M | ||
| Q1 25 | $99.9M | $35.6M | ||
| Q4 24 | $122.7M | $23.5M | ||
| Q3 24 | $130.3M | $11.1M | ||
| Q2 24 | $114.0M | $3.2M |
总债务ATRCSHLS
| Q1 26 | $61.0M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $61.9M | — | ||
| Q2 25 | $61.9M | — | ||
| Q1 25 | $61.9M | $141.8M | ||
| Q4 24 | — | $141.8M | ||
| Q3 24 | $61.9M | $141.8M | ||
| Q2 24 | $61.9M | $146.8M |
股东权益ATRCSHLS
| Q1 26 | $491.7M | $601.6M | ||
| Q4 25 | $491.9M | $600.0M | ||
| Q3 25 | $476.5M | $589.6M | ||
| Q2 25 | $464.5M | $575.4M | ||
| Q1 25 | $454.6M | $558.9M | ||
| Q4 24 | $461.0M | $556.8M | ||
| Q3 24 | $465.0M | $545.2M | ||
| Q2 24 | $462.1M | $544.6M |
总资产ATRCSHLS
| Q1 26 | $644.0M | $1.0B | ||
| Q4 25 | $654.2M | $904.1M | ||
| Q3 25 | $635.4M | $851.8M | ||
| Q2 25 | $608.8M | $795.0M | ||
| Q1 25 | $591.6M | $788.4M | ||
| Q4 24 | $609.3M | $793.1M | ||
| Q3 24 | $615.1M | $801.3M | ||
| Q2 24 | $597.3M | $788.4M |
负债/权益比ATRCSHLS
| Q1 26 | 0.12× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.13× | — | ||
| Q2 25 | 0.13× | — | ||
| Q1 25 | 0.14× | 0.25× | ||
| Q4 24 | — | 0.25× | ||
| Q3 24 | 0.13× | 0.26× | ||
| Q2 24 | 0.13× | 0.27× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ATRC
| Appendage management | $48.4M | 34% |
| Open ablation | $39.1M | 28% |
| Other | $25.0M | 18% |
| Pain management | $22.4M | 16% |
| Minimally invasive ablation | $6.4M | 5% |
SHLS
暂无分部数据
